Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 4Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Endocrine 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Small Cell Lung Carcinoma 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Advanced Solid Tumor 1

Interventions

Carboplatin 49Etoposide 46Cisplatin 42Topotecan 39Irinotecan 21Paclitaxel 20Nivolumab 15pembrolizumab 13Gemcitabine 13atezolizumab 11Ipilimumab 11durvalumab 9Radiotherapy 9Doxorubicin 7Bevacizumab 7rovalpituzumab tesirine 6etoposide phosphate 6amrubicin 6Psychiatric Rehabilitation 6PM 01183 6Docetaxel 6Counseling 6trilaciclib 5Temozolomide 5Sunitinib 5Platinum 5Imatinib Mesylate 5Cyclophosphamide 5Bortezomib 5130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × berzosertib × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡